Level A· Stronger Clinical EvidenceRandomized Controlled TrialEurope PMC

Pharmacological agents for adults with acute respiratory distress syndrome

Lewis SR., Pritchard MW., Thomas CM., Smith AF.

Randomized Controlled Trial with a reported sample of 6299 on Systemic / IV, published in Cochrane Database Syst Rev (2019) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Cochrane Database Syst Rev (2019)
Reported sample size
6299
Source database
Europe PMC
PMID
31334568
PMCID
PMC6646953
DOI
10.1002/14651858.cd004477.pub3
Citations
128

Abstract (original English)

Background Acute respiratory distress syndrome (ARDS) is a life-threatening condition caused by direct or indirect injury to the lungs. Despite improvements in clinical management (for example, lung protection strategies), mortality in this patient group is at approximately 40%. This is an update of a previous version of this review, last published in 2004. Objectives To evaluate the effectiveness of pharmacological agents in adults with ARDS on mortality, mechanical ventilation, and fitness to return to work at 12 months. Search methods We searched CENTRAL, MEDLINE, Embase, and CINAHL on 10 December 2018. We searched clinical trials registers and grey literature, and handsearched reference lists of included studies and related reviews. Selection criteria We included randomized controlled trials (RCTs) comparing pharmacological agents with control (placebo or standard therapy) to treat adults with established ARDS. We excluded trials of nitric oxide, inhaled prostacyclins, partial liquid ventilation, neuromuscular blocking agents, fluid and nutritional interventions and medical oxygen. We excluded studies published earlier than 2000, because of changes to lung protection strategies for people with ARDS since this date. Data collection and analysis Two review authors independently assessed studies for inclusion, extracted data, and assessed risks of bias. We assessed the certain

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansAdrenal Cortex HormonesNeuromuscular Blocking AgentsPulmonary SurfactantsRespiration, ArtificialAdultRandomized Controlled Trials as TopicRespiratory Distress Syndrome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research